CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE

505(b)(2) Clinical Trials for Hydrochlorothiazide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT04495608 ↗	Fluconazole in Hypercalciuric Patients With Increased 1,25(OH)2D Levels	Recruiting	Hospices Civils de Lyon	Phase 2	2021-01-13	Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular reabsorption of calcium due to increased active vitamin D, i.e. 1,25(OH)2D, levels. The management of hypercalciuria is challenging. Classic management based on hyperhydration and dietary advice has low impact on calciuria and therefore on CKD progression. Other strategies such as hydrochlorothiazide can be proposed, however with an uncertain medical benefit in view of side effects (hypokalemia, asthenia, potential cutaneous long-term side effects). Azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels. These antifungal drugs are commonly used in neonates, infants and adults; pharmacokinetic data are well described. Recently, to improve azoles tolerance, fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 mutation (1 adult) or NPTIIc mutations (1 child), while maintaining a stable renal function. Based on these observations, the investigators hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels. The primary objective is to demonstrate that fluconazole normalizes or decreases calciuria after 4 months of treatment in patients with hypercalciuria and increased 1,25(OH)2D levels. The secondary objectives aim to describe: - the effects of fluconazole on the evolution over time of the calcium/phosphate metabolism, - the evolution of renal function, - the cohort at Baseline and after 4 months of treatment period, - the safety of fluconazole, - the onset of potential mycological resistances, - and the treatment compliance. This is a prospective, interventional, national, randomized in 2 parallel groups (1:1), controlled versus placebo, double blind trial. This study will involve patients between 10 and 50 years of age suffering from nephrolithiasis and/or nephrocalcinosis with hypercalciuria (> 0.1 mmol/kg/d) and increased 1,25 (OH)2D levels (≥ 150 pmol/l) and 25-OH-D levels (≥50 nmol/L). FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug (e.g. fluconazole) in rare renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients. If the results of this proof-of-concept randomized controlled trial are positive, the investigators will propose an extension phase to evaluate the long term efficacy and safety of fluconazole on renal and bone parameters.

All Clinical Trials for Hydrochlorothiazide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000525 ↗	Diuretics, Hypertension, and Arrhythmias Clinical Trial	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1986-07-01	To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00000525 ↗	Diuretics, Hypertension, and Arrhythmias Clinical Trial	Completed	University of California, San Francisco	Phase 3	1986-07-01	To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death.
NCT00005520 ↗	Genetic Epidemiology of Responses to Antihypertensives	Completed	National Heart, Lung, and Blood Institute (NHLBI)		1997-02-01	To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
NCT00005520 ↗	Genetic Epidemiology of Responses to Antihypertensives	Completed	Mayo Clinic		1997-02-01	To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).

Clinical Trial Conditions for Hydrochlorothiazide

Condition Name

Condition Name for Hydrochlorothiazide
Intervention	Trials
Hypertension	220
Healthy	36
Essential Hypertension	33
Type 2 Diabetes Mellitus	8

Condition MeSH

Condition MeSH for Hydrochlorothiazide
Intervention	Trials
Hypertension	267
Essential Hypertension	56
Diabetes Mellitus	21
Diabetes Mellitus, Type 2	16

Clinical Trial Locations for Hydrochlorothiazide

Trials by Country

Trials by Country for Hydrochlorothiazide
Location	Trials
United States	696
Germany	72
Canada	46
Japan	42
Spain	32

Trials by US State

Trials by US State for Hydrochlorothiazide
Location	Trials
Texas	38
Florida	33
New Jersey	31
California	31
North Carolina	25

Clinical Trial Progress for Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE1	1

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide
Clinical Trial Phase	Trials
Completed	307
Unknown status	23
Recruiting	19

Clinical Trial Sponsors for Hydrochlorothiazide

Sponsor Name

Sponsor Name for Hydrochlorothiazide
Sponsor	Trials
Novartis	54
Boehringer Ingelheim	36
Merck Sharp & Dohme Corp.	17

Sponsor Type

Sponsor Type for Hydrochlorothiazide
Sponsor	Trials
Industry	293
Other	262
NIH	11

Hydrochlorothiazide: Clinical Trials, Market Landscape, and Future Projections

Last updated: February 19, 2026

Hydrochlorothiazide (HCTZ), a thiazide diuretic, remains a cornerstone therapy for hypertension and edema. Its established efficacy, favorable safety profile, and low cost contribute to its widespread use. Recent clinical trial activity, while not characterized by groundbreaking novel indications, focuses on optimizing existing use, comparative effectiveness, and combination therapies. The market for HCTZ is mature, driven by generic competition, but stable due to its essential role in managing chronic conditions. Future projections indicate continued steady demand, with potential for incremental growth through combination product development and expanded access in emerging markets.

What Are the Latest Clinical Trial Developments for Hydrochlorothiazide?

Clinical trial activity for hydrochlorothiazide (HCTZ) is characterized by ongoing studies exploring its role in specific patient populations, comparative effectiveness against other antihypertensives, and its inclusion in fixed-dose combination products. While no novel broad indications are currently under active investigation, the existing research aims to refine its therapeutic positioning and address unmet needs in managing cardiovascular and renal diseases.

Active Clinical Trial Registrations

As of the latest available data, there are a number of active clinical trials involving hydrochlorothiazide, primarily registered on clinicaltrials.gov. These trials span various phases, from early-stage safety and pharmacokinetic studies to later-stage efficacy and comparative studies.

• Phase II Trials: These studies often investigate HCTZ in combination with other agents or assess its efficacy in specific subpopulations. For example, trials may explore HCTZ’s effect on fluid balance in patients with specific renal impairments or its impact on cardiovascular outcomes when co-administered with novel compounds.
• Phase III Trials: Larger, multi-center trials are evaluating HCTZ in comparative settings. This includes head-to-head comparisons with other diuretic classes (e.g., loop diuretics in specific edema scenarios) or other classes of antihypertensives (e.g., ACE inhibitors, ARBs) to establish non-inferiority or superiority in certain endpoints, such as blood pressure reduction or organ protection.
• Phase IV Trials (Post-Marketing Studies): A significant portion of ongoing research falls into this category. These trials focus on long-term safety, real-world effectiveness, drug-drug interactions, and patient adherence in diverse, unselected populations. Studies examining HCTZ in elderly patients, individuals with comorbid conditions like diabetes, or specific ethnic groups are common.

A notable trend is the investigation of HCTZ as part of fixed-dose combination (FDC) therapies. These trials aim to improve patient compliance and achieve synergistic therapeutic effects by combining HCTZ with other antihypertensive agents, such as angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs).

Example of Ongoing Trial Focus Areas:

• Renal Impairment: Investigating the efficacy and safety of HCTZ in patients with varying degrees of chronic kidney disease, particularly concerning its diuretic effect and potential impact on electrolyte balance.
• Heart Failure Management: Assessing the role of HCTZ as an adjunct therapy for fluid management in patients with mild to moderate heart failure, often in comparison to or in addition to loop diuretics.
• Cardiovascular Event Reduction: While HCTZ is a foundational therapy, newer trials may explore its contribution to reducing specific cardiovascular events, such as stroke or myocardial infarction, when used in comprehensive treatment regimens, particularly in FDC products.
• Subgroup Efficacy: Examining potential differences in HCTZ response across different demographic groups, including age, sex, and ethnicity, to personalize treatment strategies.

Notable Trial Completions and Publications

Several recent trial completions and subsequent publications provide updated insights into HCTZ's therapeutic profile. These often refine our understanding of its efficacy, safety, and optimal dosing in specific clinical contexts.

• Comparative Efficacy Studies: Publications from trials comparing HCTZ to other diuretics have reinforced its position as a cost-effective first-line agent for mild to moderate hypertension, particularly in comparison to more potent loop diuretics for non-severe edema.
• Combination Therapy Efficacy: Studies evaluating FDCs containing HCTZ have demonstrated improved blood pressure control and patient adherence compared to monotherapy with individual components. These findings support the broader adoption of FDCs in clinical practice.
• Long-Term Safety Data: Real-world evidence from large observational studies and post-marketing surveillance data continue to affirm HCTZ's generally favorable long-term safety profile, with common side effects including hypokalemia and hyponatremia. Rare but serious adverse events remain consistently identified.

The ongoing clinical development, though incremental, sustains HCTZ's relevance by ensuring its optimal use within evolving treatment paradigms and by supporting its integration into more convenient combination therapies.

What Is the Current Market Landscape for Hydrochlorothiazide?

The market for hydrochlorothiazide (HCTZ) is characterized by its maturity, driven by its status as a widely available generic medication. Its established therapeutic profile, affordability, and broad utility in managing prevalent chronic conditions ensure consistent demand.

Market Size and Key Drivers

The global market for HCTZ is substantial, with annual sales measured in hundreds of millions of dollars. The primary drivers of this market include:

• Prevalence of Hypertension and Edema: These conditions affect millions worldwide, making HCTZ a staple treatment. The aging global population further exacerbates the prevalence of these conditions.
• Generic Availability: HCTZ has been off-patent for decades, leading to intense generic competition. This competition has driven down prices, making HCTZ highly accessible and cost-effective for healthcare systems and patients.
• Essential Medicine Status: HCTZ is listed on the World Health Organization's List of Essential Medicines, underscoring its importance in global public health and ensuring its continued availability and accessibility.
• Fixed-Dose Combinations (FDCs): The market is significantly influenced by FDCs that combine HCTZ with other antihypertensive agents (e.g., ACE inhibitors, ARBs, beta-blockers). These FDCs simplify treatment regimens, improve patient adherence, and contribute to the overall market volume for HCTZ.

Competitive Landscape

The competitive landscape for HCTZ is dominated by generic manufacturers. The market is highly fragmented, with numerous players offering HCTZ in various formulations (tablets, capsules) and dosages.

• Major Generic Manufacturers: Companies such as Teva Pharmaceutical Industries, Mylan (now Viatris), Sandoz (a Novartis division), and numerous others are key suppliers.
• Brand Name vs. Generic: While branded versions of HCTZ (e.g., Esidrix, Hydrodiuril) were historically significant, the market is now overwhelmingly dominated by generic equivalents due to price advantages.
• Formulation Diversity: While the standard tablet form is most common, the availability of different tablet strengths (e.g., 12.5 mg, 25 mg, 50 mg) caters to varied prescribing needs.

Pricing and Reimbursement

The pricing of HCTZ is highly competitive due to genericization.

• Low Price Point: The average selling price for generic HCTZ is exceptionally low, often in the range of a few cents per tablet, making it one of the most affordable prescription medications globally.
• Reimbursement Policies: HCTZ is widely covered by public and private health insurance plans worldwide. Its low cost and essential medicine status ensure favorable reimbursement policies, further driving its utilization. Healthcare systems often prioritize generic HCTZ for formulary inclusion.

Regional Market Dynamics

The market dynamics for HCTZ vary by region, influenced by healthcare infrastructure, regulatory environments, and disease prevalence.

• Developed Markets (North America, Europe): In these regions, HCTZ is a mature product, primarily used as a first-line agent for mild to moderate hypertension and as a component of FDCs. Market growth is slow, driven by population demographics and the increasing use of FDCs.
• Emerging Markets (Asia, Africa, Latin America): These markets represent significant growth potential. The rising prevalence of chronic diseases, increasing healthcare access, and the demand for affordable medications make HCTZ a critical therapeutic option. Government initiatives to expand access to essential medicines also support market growth.

The market for HCTZ, despite its maturity, remains robust due to its indispensable role in managing widespread chronic diseases, its cost-effectiveness, and its integration into combination therapies.

What Are the Future Projections for Hydrochlorothiazide?

The future outlook for hydrochlorothiazide (HCTZ) is characterized by sustained demand, driven by its fundamental role in managing prevalent chronic conditions, alongside incremental growth opportunities stemming from combination therapies and market expansion in developing regions. Significant market disruption is unlikely due to its established generic status and cost-effectiveness.

Market Growth and Demand Forecast

The global market for HCTZ is projected to experience stable, albeit modest, growth over the next five to ten years.

• CAGR Projection: Analysts project a Compound Annual Growth Rate (CAGR) for the HCTZ market in the range of 2% to 4% globally. This growth is primarily driven by increasing disease prevalence and market penetration in emerging economies.
• Driver of Sustained Demand: The persistent and growing global burden of hypertension and edema, coupled with the aging population, will continue to be the primary drivers of HCTZ demand. Its role as a foundational therapy for mild to moderate hypertension remains unchallenged by newer agents in terms of cost-effectiveness.
• Volume vs. Value Growth: While the volume of HCTZ units dispensed is expected to grow steadily, the value growth will be tempered by the continued price competition among generic manufacturers.

Opportunities for Growth

Several factors present opportunities for HCTZ market expansion:

• Expansion of Fixed-Dose Combinations (FDCs): The trend towards FDCs that incorporate HCTZ with other antihypertensive agents (e.g., ARBs, ACEIs, potassium-sparing diuretics) is a significant growth driver. These combinations offer improved patient adherence and synergistic therapeutic benefits, leading to increased market share for HCTZ as a component. New FDC formulations and combinations are likely to emerge.
• Emerging Market Penetration: As healthcare infrastructure improves and access to essential medicines expands in emerging economies in Asia, Africa, and Latin America, the demand for affordable and effective treatments like HCTZ is expected to rise significantly. Government programs aimed at managing non-communicable diseases will further bolster this growth.
• Repurposing and Niche Indications: While broad new indications are improbable, ongoing research may identify specific niche applications or refined uses of HCTZ in conjunction with other therapies for particular patient subsets (e.g., certain types of resistant hypertension, specific edema etiologies).

Challenges and Market Dynamics

Despite its strong market position, HCTZ faces certain challenges:

• Genericization and Price Erosion: The highly genericized nature of the market leads to intense price competition, limiting significant value growth for individual manufacturers. Profit margins for HCTZ monotherapy are typically low.
• Competition from Newer Agents: While HCTZ remains a first-line option for many, newer classes of antihypertensives with potentially more favorable side effect profiles or specific organ-protective benefits are increasingly used in later lines of therapy or for specific patient profiles.
• Adverse Event Management: Potential side effects such as hypokalemia, hyponatremia, and metabolic disturbances, while manageable, require careful patient monitoring and may necessitate the use of combination therapies or alternative agents in sensitive populations.

Technological and Formulation Innovations

Future innovation in the HCTZ market is likely to focus on formulation and delivery rather than novel drug discovery.

• Improved FDC Formulations: Development of more patient-friendly FDC formulations, potentially with enhanced bioavailability or extended-release properties, could drive adoption.
• Combination Therapies: Research and development efforts will continue to focus on identifying optimal combinations of HCTZ with other established or novel therapeutic agents to address complex patient needs more effectively.

The future of HCTZ is one of sustained relevance and steady, incremental growth. Its position as a cost-effective, essential medicine, particularly when integrated into advanced combination therapies and made more accessible in developing regions, will ensure its continued importance in global pharmacotherapy.

Key Takeaways

• Hydrochlorothiazide (HCTZ) is a mature drug with a stable market driven by its efficacy, affordability, and essential medicine status for hypertension and edema.
• Clinical trial activity is focused on optimizing existing use, comparative effectiveness, and developing fixed-dose combinations (FDCs) rather than novel indications.
• The global HCTZ market is valued in the hundreds of millions of dollars, dominated by generic manufacturers, and is projected to grow at a CAGR of 2% to 4%.
• Future growth opportunities lie in the expansion of FDCs, increased penetration in emerging markets, and potential niche applications.
• Challenges include intense price competition among generics and ongoing development of newer antihypertensive agents.

Frequently Asked Questions

1. What are the primary medical conditions treated by Hydrochlorothiazide? Hydrochlorothiazide is primarily used to treat high blood pressure (hypertension) and fluid retention (edema) associated with conditions such as heart failure, liver cirrhosis, and kidney disorders.

2. What is the typical dosage range for Hydrochlorothiazide in adult patients? The typical adult dosage for hydrochlorothiazide ranges from 12.5 mg to 50 mg once daily, though it can be adjusted by a healthcare professional based on the patient's response and tolerance.

3. Are there any significant drug interactions to be aware of with Hydrochlorothiazide? Yes, hydrochlorothiazide can interact with various medications, including other diuretics, blood pressure-lowering drugs, lithium, corticosteroids, NSAIDs, and certain diabetes medications. Patients should always inform their healthcare provider about all medications they are taking.

4. What are the most common side effects associated with Hydrochlorothiazide use? Common side effects include electrolyte imbalances such as low potassium (hypokalemia) and low sodium (hyponatremia), increased urination, dizziness, lightheadedness, and increased sensitivity to sunlight.

5. How does Hydrochlorothiazide compare in effectiveness to other common diuretic classes like loop diuretics (e.g., Furosemide)? Hydrochlorothiazide is generally considered a thiazide diuretic and is effective for mild to moderate hypertension and edema. Loop diuretics are typically more potent and are reserved for more severe cases of edema, such as in acute heart failure or significant renal impairment, where they can achieve a greater diuretic effect.

Citations

[1] U.S. National Library of Medicine. (n.d.). Hydrochlorothiazide. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ [2] World Health Organization. (2021). World Health Organization Model List of Essential Medicines. [3] Pharmaceutical market research reports (various publishers, 2022-2023).